Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 11497801
    Abstract: A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: November 15, 2022
    Inventors: Sherryll Layton, Jeffrey W. Hall
  • Patent number: 11484572
    Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: November 1, 2022
    Assignees: UNIVERSITÄT BASEL, UNIVERSITÄT ZURICH
    Inventors: Osiris Marroquin Belaunzaran, Christoph Renner, Ulf Petrausch
  • Patent number: 11472888
    Abstract: The present invention provides methods and compositions for treating atherosclerosis in a subject comprising the use of therapeutic compounds to reduce Reelin in the circulation of the subject, thereby reducing the adhesion of leukocytes to the vascular wall. The invention also provides methods and compositions for reducing leukocyte adhesion to the vascular wall in a subject.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: October 18, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Joachim Herz, Yinyuan Ding, Xunde Xian, Linzhang Huang, Chieko Mineo, Philip Shaul, Laurent Calvier
  • Patent number: 11459370
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 4, 2022
    Assignee: Amgen Inc.
    Inventors: Heather Arnett, Sabine Schadow Escobar, Ryan Michael Swanson, Joanne Louise Viney
  • Patent number: 11458477
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • Patent number: 11453720
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 27, 2022
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Nels P. Nielson, Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Heather Brodkin, Jose-Andres Salmeron-Garcia, Christopher James Nirschl, Philipp Steiner
  • Patent number: 11447557
    Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 20, 2022
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
  • Patent number: 11434294
    Abstract: The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: September 6, 2022
    Assignee: Cell Medica, Inc.
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar, Miriam Droste, Douglas Phillips
  • Patent number: 11421032
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies, and antigen-binding fragments thereof, that specifically bind to MICA/B ?3 domain, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 23, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Lucas Ferrari de Andrade, Kai W. Wucherpfennig
  • Patent number: 11421026
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 23, 2022
    Assignee: Bird Rock Bio, Inc.
    Inventors: Anke Kretz-Rommel, Roger Ferrini
  • Patent number: 11421021
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a LukAB-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 23, 2022
    Assignee: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
    Inventors: Thomas Kort, Nils Williston, Shweta Kailasan, Hatice Karauzum, Rajan P. Adhikari, Mohammad Javad Aman
  • Patent number: 11396554
    Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 26, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Hatem Soliman
  • Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • Patent number: 11359024
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 14, 2022
    Assignees: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • Patent number: 11318210
    Abstract: The present disclosure relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma. The antibody has the ability to become internalized in Endosialin expressing cells and to block the activation of MAPK in PDGF stimulated human pericytes. The antibody is able to block angiogenesis induced by LGALS3BP, a known Endosialin interactor and to inhibit tumor growth alone and in combination with 1959, a humanized antibody against LGALS3BP in human osteosarcoma xenograft. Furthermore, upon conjugation of the humanized version of the anti-Endosialin antibody with a duocarmycin derivative, the resulting ADC displays potent and antigen dependent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo. The disclosure is also related to nucleotides encoding the antibodies of the disclosure and cell expressing the antibodies.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 3, 2022
    Assignee: Fusion Pharmaceuticals Inc.
    Inventors: Stefano Iacobelli, Annalisa Di Risio, Enza Piccolo, Gianluca Sala, Emily Capone
  • Patent number: 11299538
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: April 12, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Patent number: 11285179
    Abstract: The invention surprisingly found that Lactobacillus plantarum subsp. plantarum PS128 provides an advantageous effect in treatment or prevention of tic disorders and basal ganglia disorders. Accordingly, the invention provides a method of treating or preventing a movement disorder in a subject, comprising administering to a subject an effective amount of cells of a Lactobacillus plantarum subsp. plantarum PS128, which is deposited under DSMZ Accession No. DSM 28632.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 29, 2022
    Assignees: BENED BIOMEDICAL CO., LTD., ASIAN PROBIOTICS AND PREBIOTICS CORPORATION
    Inventors: Ying-Chieh Tsai, Chih-Chieh Hsu, Jian-Fu Liao, Yun-Fang Cheng, Shu-Ting You
  • Patent number: 11279754
    Abstract: One aspect of the invention provides a method for treating a cancer including administering to a subject in need of such treatment a composition including a therapeutically effective amount of an antibody directed against p40 monomer or an immunologically active fragment thereof. In various embodiments, the antibody is a polyclonal, monoclonal, human, humanized, and chimeric antibody; a single chain antibody or an epitope-binding antibody fragment. In other embodiments, the cancer is, for example, prostate cancer, breast cancer or liver cancer.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: March 22, 2022
    Assignee: RUSH UNIVERSITY MEDICAL CENTER
    Inventor: Kalipada Pahan
  • Patent number: 11278618
    Abstract: The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using Interleukin-17 (IL-17) antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: March 22, 2022
    Assignee: NOVARTIS AG
    Inventors: Shephard Mpofu, Hanno Richards, Gregory Ligozio
  • Patent number: 11274145
    Abstract: The invention provides antibodies that bind mixed-topology polyubiquitin and multispecific anti-polyubiquitin antibodies, and methods of using the same.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 15, 2022
    Assignee: Genentech, Inc.
    Inventors: Vishva Dixit, Marissa Matsumoto, Erick Castellanos
  • Patent number: 11274350
    Abstract: The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 15, 2022
    Assignee: CEMM—Forschungszentrum für Molekulare Medizin GmbH
    Inventors: Robert Kralovics, Thorsten Klampfl, Heinz Gisslinger
  • Patent number: 11274146
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5a antibody.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 15, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Sayaka Sato, Takashi Miwa, Damodar Gullipalli
  • Patent number: 11274154
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 15, 2022
    Assignees: PFIZER INC., MERCK PATENT GMBH
    Inventors: Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
  • Patent number: 11267888
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 8, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • Patent number: 11268067
    Abstract: Disclosed herein are methods of isolating SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells isolated by said methods.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 8, 2022
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Jack Kavanaugh, Larry A. Couture, Lisa O'Flynn
  • Patent number: 11261242
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan
  • Patent number: 11254730
    Abstract: The present invention provides a recombinant protein or a derivative thereof, wherein the recombinant protein has an amino acid sequence of the N-terminal portion of CC chemokine receptor 4 (CCR4). The invention also provides the use of the recombinant protein or a derivative thereof for treating or preventing a disease or condition associated with CCR4 signaling, such as an allergic disease, inflammatory enteritis, psoriasis, an inflammatory skin disease, vasculitis, spondyloarthropathy, scleroderma, asthma, a respiratory allergic disease, an autoimmune disease, graft rejection, leukemia, lymphoma, a blood-borne cancer, a disease requiring inhibition of undesirable inflammation, and a cancer.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 22, 2022
    Assignee: Institute of Biophysics, Chinese Academy of Sciences
    Inventors: Pengyuan Yang, Yanan Gao, Maojun You
  • Patent number: 11253570
    Abstract: The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-?B-associated postnatal inflammatory disorder.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: February 22, 2022
    Assignees: Medizinische Hochschule Hannover (MHH), Westfalische Wilhelms-Universität Münster
    Inventors: Dorothee Viemann, Johannes Roth, Thomas Vogl
  • Patent number: 11160837
    Abstract: Provided are Megamonas funiformis and applications thereof. Specifically, the Megamonas funiformis has the effects for preventing and/or treating inflammation-related diseases, such as inflammatory bowel diseases (such as ulcerative enteritis, gastritis, and general enteritis) and cardiovascular diseases.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 2, 2021
    Assignee: BGI SHENZHEN
    Inventors: Yuanqiang Zou, Liang Xiao, Xiaoping Li, Jinghong Yu, Chuan Liu
  • Patent number: 11154616
    Abstract: The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventor: Daniel ShinYu Chen
  • Patent number: 11124556
    Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Immunocore Limited, Adaptimmune Limited
    Inventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
  • Patent number: 11111271
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 7, 2021
    Assignee: COHBAR, INC.
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • Patent number: 11103551
    Abstract: The present invention is related to a method or a pharmaceutical composition for treatment or prevention of a cancer through blocking the interaction of ?4 integrin and focal adhesion kinase (FAK).
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 31, 2021
    Inventors: Tang-Long Shen, Yu-Ling Tai, Hsin-Jung Wu
  • Patent number: 11078239
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 3, 2021
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Patent number: 11078272
    Abstract: Methods are provided for targeting pediatric brain tumor cells for depletion.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 3, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Sharareh Gholamin, Samuel Cheshier, Siddhartha S. Mitra, Irving L. Weissman
  • Patent number: 11072655
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: July 27, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman, Siddhartha Jaiswal, Mark P. Chao
  • Patent number: 11059910
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 13, 2021
    Assignee: NovImmune SA
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
  • Patent number: 11047651
    Abstract: An armor component that includes a ballistic tile made of, for example, boron carbide or silicon carbide, a plurality of wraps made of ballistic fibers such as carbon fiber, and a metal plate, for example, a steel plate, the metal plate being positioned behind the reverse side of the tile and the wraps being wrapped around the tile and the metal plate.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: June 29, 2021
    Assignee: VERCO MATERIALS, LLC
    Inventors: Robert F. Speyer, John Shupe
  • Patent number: 11046782
    Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 29, 2021
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventor: Zihai Li
  • Patent number: 11033616
    Abstract: The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 15, 2021
    Inventors: Hervé Poulet, Veljko Nikolin, Abraham Johannes De Smit, Teshome Mebatsion
  • Patent number: 11028172
    Abstract: Provided are anti-TIGIT antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the TIGIT protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 8, 2021
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11014990
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 25, 2021
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 11013815
    Abstract: Human anti-human folate receptor beta (FR?) antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat a disorder, including but not limited to inflammatory disorders or cancers expressing cell surface FR?.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 25, 2021
    Assignee: Monojul, LLC
    Inventors: Cheryl Nickerson-Nutter, David Smolin
  • Patent number: 11007146
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: May 18, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • Patent number: 11001607
    Abstract: The peptide has from 3 to 10 amino acids comprising at least the sequence K*(Ac)GH or K*(Ac)HG and may further comprise an N-terminus modification, preferably an acylation, and/or a C-terminus modification; K* is selected from the group consisting of lysine, ornithine, diaminobutyric acid, diaminopropionic acid and a hydroxylated derivative thereof; K*(Ac) corresponds to a lysine, ornithine, diaminobutyric acid, diaminopropionic acid or a hydroxylated derivative thereof, acetylated on the amine of their lateral hydrocarbon chain. The two preferred peptides are Pal-K(Ac)GH and Pal-K(Ac)HG. This peptide can be used for a cosmetic treatment, in particular anti-aging, anti-wrinkle and fine lines, to improve the mechanical properties of the skin, firmness/tonicity/elasticity/flexibility, to increase the density and volume of the skin, for a restructuring, healing effect, and/or to fight stretch marks.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 11, 2021
    Assignee: Sederma
    Inventors: Olivier Peschard, Anne Doucet, Richard Leroux, Philippe Mondon
  • Patent number: 10989718
    Abstract: Methods and kits are provided for amplifying and detecting ?S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded ?S protein may include: contacting the sample with a monomeric, folded ?S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded ?S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded ?S protein in the presence of the soluble, misfolded ?S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded ?S aggregate present; and determining the presence of the soluble, misfolded ?S protein in the sample by detecting at least a portion of the soluble, misfolded ?S protein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 27, 2021
    Assignees: Amprion, Inc., The Board of Regents of the University of Texas System
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Patent number: 10973867
    Abstract: Methods for treating retinopathy are provided and include administering an effective amount of a polypeptide antagovist of a Na/K ATPase/Src receptor complex to a subject. The retinopathy can include diabetic retinopathy. Methods of decreasing angiogenesis in a retinal vasculature are also provided and include the step of administering, such as by intravitreous injection, a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 13, 2021
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Zijian Xie, Joseph I. Shapiro
  • Patent number: 10975134
    Abstract: The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 13, 2021
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Patent number: 10955420
    Abstract: This document relates to materials and methods for identifying and monitoring immunoglobulin cleavage (e.g., IgG cleavage) in a sample, such as a biological sample, using mass spectrometry techniques.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 23, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: David R. Barnidge, David L. Murray
  • Patent number: 10919959
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel